Abciximab induced severe thrombocytopenia in an elderly patient

Aastha Sen; Neena Bhatti; Girish Joseph; Vinay Gautam

doi:10.18203/2319-2003.ijbcp20223252

Authors

Aastha Sen Department of Pharmacology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, Himachal Pradesh, India
Neena Bhatti Department of Pharmacology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, Himachal Pradesh, India
Girish Joseph Department of Pharmacology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, Himachal Pradesh, India
Vinay Gautam Department of Pharmacology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, Himachal Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20223252

Keywords:

Abciximab, Thrombocytopenia, Percutaneous coronary interventions

Abstract

Abciximab is a humanized monoclonal antibody which acts against α_IIbβ₃ receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients. The drug has been notorious to cause bleeding and also decrease in the number of platelets. In this case the patient had normal platelet count but the count decreased significantly after abciximab was given. A number of cases have been reported but very few have been reported from India. Hence, we found it important to report and it is a valuable asset for scientific research.

Metrics

Metrics Loading ...

Author Biography

Girish Joseph, Department of Pharmacology, Dr. Yashwant Singh Parmar Government Medical College, Nahan, Himachal Pradesh, India

Assistant Professor in Department of Pharmacology at Christian Medical College, Ludhiana

References

Brunton LL, Chabner BA, Knollman BC. The pharmacological basis of therapeutics. 13th ed. New Delhi: Mcgraw Hill. 2018.

Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-8.

Topol EJ, Byzova TV, Plow EF. Platelet GP IIb-IIIa blockers. Lancet. 1999;353:227-31.

Peters MN, Press CD, Moscona JC, Syed RH, Katz MJ, Egan AA et al. Acute profound thrombocytopenia secondary to local abciximab infusion. Proc (Bayl Univ Med Cent). 2012t;25(4):346-8.

Adverse drug Naranjo probability scale. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548069/. Accessed on 27 Oct, 2022.

Califf RM, Abdelmeguid AE, Kuntz RE. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-51.

Anderson KM, Califf RM, Stone GW, Neuman FJ, Montalescot G, Miller DP et al. Long-Term Mortality Benefit With Abciximab in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2001;37:2059-65.

Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. The Lancet. 2002;359(9310):920-5.

Bai N, Niu Y, Ma Y, Shang YS, Zhong PY, Wang ZL. Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials. J Interventional Cardiol. 2022;2022.

Vincent L, Bourneau-Martin D, Maurier A, Babin M, Delepine S, Helley D et al. Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review. Therapies. 2021;76(6):687-93.